In a significant move that highlights the ongoing battle against escalating drug prices, Cigna Corp's Express Scripts has reached a settlement with the U.S. Federal Trade Commission (FTC) regarding allegations that its pricing strategies for insulin violated antitrust laws and consumer protection regulations. According to a document reviewed by Reuters, this agreement not only addresses these claims but also commits to reforms designed to lower expenses for patients, health insurers, and smaller pharmacies.
Under the previous Trump administration, efforts were intensified to tackle high pharmaceutical costs, culminating in agreements with various drug manufacturers aimed at reducing prices. This settlement aligns with those objectives and enables the FTC to streamline a case initiated by the Biden administration against Cigna's Express Scripts, as well as against UnitedHealth Group Inc's Optum division and CVS Health Corp's CVS Caremark. It is noteworthy that investigations involving Optum and Caremark are still ongoing.
Pharmacy benefit managers (PBMs), which determine how medications are covered under health insurance plans, have been scrutinized for their pricing practices for over a decade. Although the industry has already implemented some reforms, this settlement empowers the FTC to enforce more extensive changes at Express Scripts.
The agreement spans ten years and places restrictions on Express Scripts, particularly concerning practices that critics argue contribute to inflated drug prices, such as retaining rebate payments from drug manufacturers based on the drugs' list prices. A senior official from the FTC estimated that these measures could save patients approximately $7 billion over the next decade.
While Express Scripts announced a transition away from rebate practices last year, this settlement legally binds the company to comply and subjects it to three years of oversight to ensure adherence to the new rules.
The FTC has accused major pharmacy benefit managers of guiding both insurers and patients toward higher-priced medications instead of more affordable alternatives, thereby maximizing profit margins. In 2024, the FTC filed a lawsuit against Express Scripts, Optum, and CVS Caremark, alleging that they unfairly excluded lower-cost insulin products from the lists of medications covered by insurance plans.
Additionally, the terms of Express Scripts' settlement mandate collaboration with local pharmacies and require annual disclosures of drug prices to employers, enhancing transparency in the process.
As part of this agreement, Express Scripts will also relocate Ascent Health Services, a rebate aggregator based in Switzerland, to the United States.
Cigna predominantly operates by managing health plans for employers and other groups that cover medical expenses. The settlement stipulates that Cigna must account for any direct-to-consumer drug purchases made through the upcoming TrumpRX platform against copayments and deductibles within its standard employer-offered plans.
In recent years, companies like CVS, UnitedHealth, and Cigna have introduced new pricing models aimed at providing clearer insights into discounts, fees, and drug costs. They increasingly assert that their revenue derives from administrative fees rather than concealed reimbursements from pharmaceutical companies.
This entire scenario raises important questions: Can we trust that these changes will lead to genuinely lower prices? Will the promised savings materialize for everyday patients? And what other systemic changes are necessary to ensure fair drug pricing in the future?
